Lu Hsiao-Ming
Francis H. Burr Proton Therapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Phys Med Biol. 2008 Dec 7;53(23):N415-22. doi: 10.1088/0031-9155/53/23/N01. Epub 2008 Nov 7.
Range uncertainty in proton therapy is a recognized concern. For certain treatment sites, less optimal beam directions are used to avoid the potential risk, but also with reduced benefit. In vivo dosimetry, with implanted or intra-cavity dosimeters, has been widely used for treatment verification in photon/electron therapy. The method cannot, however, verify the beam range for proton treatment, unless we deliver the treatment in a different manner. Specifically, we split the spread-out Bragg peaks in a proton field into two separate fields, each delivering a 'sloped' depth-dose distribution, rather than the usual plateau in a typical proton field. The two fields are 'sloped' in opposite directions so that the total depth-dose distribution retains the constant dose plateau covering the target volume. By measuring the doses received from both fields and calculating the ratio, the water-equivalent path length to the location of the implanted dosimeter can be verified, thus limiting range uncertainty to only the remaining part of the beam path. Production of such subfields has been experimented with a passive scattering beam delivery system. Phantom measurements have been performed to illustrate the application for in vivo beam range verification.
质子治疗中的射程不确定性是一个公认的问题。对于某些治疗部位,会采用不太理想的射束方向以避免潜在风险,但这样做的益处也会减少。在光子/电子治疗中,使用植入式或腔内剂量计进行体内剂量测定已被广泛用于治疗验证。然而,该方法无法验证质子治疗的射束射程,除非我们以不同的方式进行治疗。具体而言,我们将质子场中的扩展布拉格峰分成两个单独的场,每个场提供一个“倾斜”的深度剂量分布,而不是典型质子场中常见的平台状分布。这两个场的“倾斜”方向相反,以便总深度剂量分布保持覆盖靶区的恒定剂量平台。通过测量从两个场接收的剂量并计算比值,可以验证到植入剂量计位置的水等效路径长度,从而将射程不确定性仅限制在射束路径的其余部分。已经使用被动散射束流输送系统对这种子场的产生进行了实验。已进行模体测量以说明其在体内射束射程验证中的应用。